Creating a test to identify aggressive breast cancers that express ADAM8.
Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers
This study is working on a new test to find a specific type of breast cancer that has a marker called ADAM8, especially the more aggressive triple-negative kind, so that doctors can offer better treatments tailored just for those patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Adecto Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Brookline, United States) |
| Project ID | NIH-10685491 on NIH RePORTER |
What this research studies
This research focuses on developing a diagnostic test to detect ADAM8-positive breast cancers, particularly the aggressive triple-negative subtype. By identifying patients with this specific marker, the study aims to tailor targeted therapies that could improve treatment outcomes. The approach involves using mouse models to test antibody-based treatments that target ADAM8, which has been shown to inhibit tumor growth and enhance survival rates. The ultimate goal is to provide a reliable diagnostic tool that can guide treatment decisions for patients with ADAM8-positive cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who may express the ADAM8 marker.
Not a fit: Patients with hormone receptor-positive or HER2-positive breast cancers are unlikely to benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with aggressive breast cancers, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting similar markers in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Brookline, United States
- Adecto Pharmaceuticals, INC. — Brookline, United States (Active)
Researchers
- Principal investigator: Sonenshein, Gail E. — Adecto Pharmaceuticals, INC.
- Study coordinator: Sonenshein, Gail E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.